Please login to the form below

Not currently logged in
Email:
Password:

cangrelor

This page shows the latest cangrelor news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

cangrelor. Kengrexal. percutaneous coronary intervention (PCI). P2Y12 inhibitor. The Medicines Company.

Latest news

  • FDA gives the nod to TMC's antiplatelet drug FDA gives the nod to TMC's antiplatelet drug

    Kengreal (cangrelor) has been approved by the FDA for adult patients undergoing percutaneous coronary intervention (PCI) to open a blocked or narrowed coronary artery, three months after being given a green ... TMC's efforts to bring cangrelor to market

  • AZ and Takeda drugs should carry heart failure warning AZ and Takeda drugs should carry heart failure warning

    Cangrelor go-ahead. Meanwhile, the FDA's advisory committee also voted 9 to 2 in favour of approving The Medicines Company's injectable anticoagulant cangrelor as an adjunct to percutaneous coronary ... The FDA is due to deliver a final decision on

  • FDA reviewer backs approval of TMC's cangrelor FDA reviewer backs approval of TMC's cangrelor

    FDA reviewer backs approval of TMC's cangrelor. Claims it offers a small benefit over Sanofi’ s Plavix. ... Analysts had at one point been predicting sales of cangrelor could reach upwards of $500m, but expectations are now more modest with estimates

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Kengrexal (cangrelor) was recommended for use in the reduction of thrombotic cardiovascular events in adults with coronary artery disease.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics